Best Essential Thrombocythaemia Treatment Doctors in India
Whatsapp Us
Dr. Utpal Chaudhuri
Dr. Ramesh Uppada
Dr. Ashish Dixit
Dr. Madala Ravikrishna
Dr. Rajendra Pol
Dr. Joydeep Chakrabartty
Dr. Satya Pal Kataria
Dr. Jasashwi Chakraborty
Dr. Roshan Dikshit
Dr. Faran Naim
What Patients with Essential Thrombocythaemia Worry About Most
Essential thrombocythaemia is often found by accident when a routine blood test shows a very high platelet count. Patients ask: am I at risk of a stroke or heart attack, do I need to be on medication for life, can the disease turn into leukaemia, and is it safe to get pregnant. The fear of a clotting event (stroke, heart attack, deep vein thrombosis) is real because high platelet counts and underlying mutations like Janus kinase 2 mutation do raise the risk. With proper risk stratification and treatment, most patients live a normal lifespan and the rate of serious events is low.
How Essential Thrombocythaemia Is Diagnosed
Diagnosis requires persistently elevated platelet counts (above 450 thousand per microlitre), bone marrow biopsy showing characteristic megakaryocyte changes, exclusion of other causes of thrombocytosis, and detection of a driver mutation. The mutation panel includes Janus kinase 2 (V617F and exon 12), calreticulin (type 1 and type 2), and myeloproliferative leukaemia virus oncogene. Around fifty to sixty percent of patients have a Janus kinase 2 mutation, twenty to twenty-five percent have calreticulin, and three to five percent have myeloproliferative leukaemia virus oncogene. Other causes of high platelets including iron deficiency, infection, and other myeloproliferative disorders must be excluded. Risk stratification (low, intermediate, or high) is based on age, previous thrombosis, Janus kinase 2 mutation status, and cardiovascular risk factors.
Treatment Options for Essential Thrombocythaemia in India
The goal is to reduce the risk of thrombosis and bleeding while minimising long-term side effects of cytoreductive therapy. Low-risk patients are usually managed with low-dose aspirin alone. Intermediate-risk patients may need aspirin plus cytoreduction. High-risk patients need cytoreductive therapy. Hydroxyurea is the first-line cytoreductive agent. Pegylated interferon alpha is preferred in younger patients, pregnant patients, and those who want to avoid hydroxyurea’s potential long-term effects. Anagrelide selectively reduces platelets and is an option for patients who cannot tolerate hydroxyurea or interferon. Ruxolitinib is reserved for difficult cases not responding to standard therapy. Centres at Fortis Memorial Research Institute, Medanta, BLK-Max, Apollo, and Tata Memorial run myeloproliferative neoplasm clinics with full access to mutation testing and the range of cytoreductive options.
Recovery, Success Rates, and Follow-Up
Most patients live a normal lifespan with proper risk-adapted treatment. The annual rate of thrombosis is around one to three percent on treatment, down from around five to ten percent untreated. Transformation to myelofibrosis happens in around five to ten percent over fifteen to twenty years, and transformation to acute myeloid leukaemia is uncommon. There is no hospital stay required. Patients take daily oral hydroxyurea or weekly interferon injections at home, with clinic visits every three months for blood counts. Pregnant patients need closer monitoring and may switch from hydroxyurea to interferon.
How to Choose the Right Doctor
Look for a doctor with at least ten years of haematology experience, working at a centre that runs Janus kinase 2, calreticulin, and myeloproliferative leukaemia virus oncogene mutation testing in-house and has access to pegylated interferon and ruxolitinib. Questions to ask: how the doctor decides between aspirin alone and cytoreduction, the approach for pregnancy, the experience with pegylated interferon, and how transformation to myelofibrosis is monitored over time. Centres at Fortis Memorial Research Institute, Medanta, BLK-Max, Apollo, and Tata Memorial have established myeloproliferative neoplasm clinics.
Support for International Patients
Treatment in India is more affordable than equivalent care in the United Kingdom, United States, Middle East, or Southeast Asia. Generic hydroxyurea manufactured in India is widely available at low cost, and pegylated interferon and anagrelide are accessible at major centres. Cancer Rounds arranges the medical visa invitation letter, accommodation, multilingual support in eleven plus languages, and ongoing coordination for long-term monitoring. Patients from Nigeria, Bangladesh, Oman, Kuwait, Qatar, Kenya, Uganda, Tanzania, Ghana, Ethiopia, Cameroon, Mauritius, Mozambique, Senegal, Zimbabwe, Zambia, Guinea, Liberia, Madagascar, South Sudan, Qatar, Chad, Sierra Leone, Congo, Iraq & Uzbekistan, and other countries consult Indian hemato-oncologists for essential thrombocythaemia.
Frequently Asked Questions
Is essential thrombocythaemia cancer?
It is classified as a myeloproliferative neoplasm, which is a chronic blood cancer. It behaves very differently from acute leukaemia. Most patients live a normal lifespan with proper management.
Do I need treatment if my platelets are only mildly elevated?
Treatment depends on risk category, not platelet count alone. Low-risk patients are managed with low-dose aspirin alone. High-risk patients need cytoreductive therapy regardless of how high the platelets are.
Hydroxyurea or pegylated interferon: what is the difference?
Hydroxyurea is a daily oral tablet that effectively lowers platelets and is well tolerated. Pegylated interferon is a weekly injection that may help reduce the disease at the molecular level over time. Interferon is preferred in younger patients, pregnant patients, and those who want to avoid hydroxyurea’s potential long-term effects.
Can I get pregnant with essential thrombocythaemia?
Yes, but pregnancy needs careful management. Hydroxyurea is stopped before conception. Pegylated interferon is the cytoreductive agent of choice during pregnancy if needed. Aspirin and low molecular weight heparin are used for clotting prevention.
Will it turn into leukaemia?
Transformation to acute myeloid leukaemia is uncommon (around one to two percent over twenty years). Progression to myelofibrosis is more common (around five to ten percent). Regular monitoring picks up either change early.
How often do I need bone marrow testing?
Bone marrow biopsy is needed at diagnosis and is usually repeated every two to three years or sooner if blood counts change, the spleen enlarges, or symptoms develop suggesting transformation.
